Alumis Inc., a late-stage biopharma company specializing in next-generation targeted therapies for immune-mediated diseases, has successfully completed its merger with ACELYRIN, Inc. This strategic move establishes a leading clinical-stage biopharma company with a robust portfolio and a strong financial position. As part of the merger, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share they own. With this merger, Alumis aims to advance its pipeline and extend its cash runway into 2027, ensuring continued development of transformative therapies for patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.